Amgen's obesity drug MariTide shows promise in maintaining weight loss with less frequent dosing. In trials, it achieved up ...

Chief Executive Officer Bob Bradway told attendees at a J.P. Morgan-hosted event that the company views 2026 as a ...

After a flurry of Big Pharma deals in the first week of the new year, the life sciences industry is heading to San Francisco ...

Amgen's experimental drug MariTide shows promise in maintaining weight loss and lowering blood sugar in diabetes patients.

An extension study of Amgen's experimental obesity drug MariTide found that it helped people maintain weight loss while ​a ...

Amgen's research chief said the company is very confident about its experimental obesity drug MariTide, as it prepares on ...

Pill versions of the successful GLP1 drugs from Novo Nordisk and Eli Lilly will likely be on the market in 2026’s first half.

The Dow Jones Industrial Average itself yields modestly, but the Dogs of the Dow 2026 pack more dividend bite.

From the King Kong of weight-loss jabs to the Godzilla of the category, the GLP-1 industry is undergoing big changes ...

Dow Jones Industrial Average, Chevron Corp, Coca-Cola Co, Merck & Company Inc. Read 's Market Analysis on Investing.com ...

After a period of lackluster performance, CVS Health (CVS) and Amgen (AMGN) staged a remarkable comeback in 2025, outperforming the broader market by a significant margin. While the overall ...